Science
Unique and proprietary antigen discovery platform
ATLAS™ is a proven secret weapon that is changing the way cancer is treated by using a unique, biology-driven approach to developing immunotherapies specific to each patient’s tumor and immune system. ATLAS zeroes in on only those neoantigens that will trigger anti-tumor T cell responses.
The only technology of its kind that can identify Inhibigens™
ATLAS is also the only technology of its kind that can identify pro-tumor inhibitory antigens, or InhibigensTM, which are detrimental to a protective immune response. A growing body of foundational research led by the Genocea team has revealed the mere presence of Inhibigens is linked to enhanced tumor growth and promotes an immune response that can undermine the efficacy of otherwise effective immunotherapies. Explore more information on this breakthrough research below:
- Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform
- “An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth”, Cancer Discovery
- “Neoantigens: Friend or foe? New insights into tumor mutations that both betray and protect cancer”, STAT
- Hear more from the team working on this pivotal research
ATLAS antigen selection: our foundation
- Included: Antigens relevant to both tumor and patient immune system
- Confirms antigens are both surface-presented and immunogenic
-
- Excluded: Inhibigens, uniquely identified by ATLAS
- CD4+ and CD8+ T cells responding to Inhibigens can promote tumor growth and compete with immunotherapy anti-tumor effects
- For any patient, any antigen type, any cancer, and both CD4+ and CD8+ T cells
- ATLAS is a highly industrialized platform
- Global patent families protect ATLAS into 2030s
How ATLAS Works
